Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Addex Pharmaceuticals S.A., Merck deal

The companies partnered to develop and market Addex's ADX63365 to treat schizophrenia and other undisclosed

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE